NewcelX appoints diabetes researcher Camillo Ricordi to scientific advisory board
The move follows a successful FDA Type B Pre-IND meeting for NCEL-101 and comes as the company advances its type 1 diabetes program and collaboration with Eledon Pharmaceuticals.